LA MPJE key terms

The state agency that licenses pharmacists, pharmacy interns, and pharmacies, adopts practice rules, and disciplines licensees for violations of the Pharmacy Practice Act.

Louisiana statute governing the practice of pharmacy, including licensing, dispensing, drug storage, and grounds for discipline; board rules adopted under it carry the force of law.

Process by which a pharmacist licensed in another state obtains a Louisiana license, typically requiring an active license in good standing, NAPLEX and MPJE scores, and board approval.

Moving an existing pharmacist license record between state boards, usually through NABP, so the receiving state can verify examination scores and disciplinary history.

The National Association of Boards of Pharmacy, which administers NAPLEX and MPJE, maintains pharmacist and pharmacy databases, and coordinates license transfer among member boards.

The Multistate Pharmacy Jurisprudence Examination, a computer-based test of federal and state pharmacy law that candidates must pass to be licensed in Louisiana.

A person registered with the board who is gaining supervised practical experience toward licensure and may perform pharmacist duties only under a licensed preceptor's direct supervision.

A licensed pharmacist approved by the board to supervise and evaluate an intern's or student's practical experience, accepting responsibility for the trainee's activities.

Mandatory credit hours, including specified live and law hours, that a Louisiana pharmacist must complete each renewal cycle to keep an active license.

The periodic process of paying fees and documenting continuing education to maintain an active Louisiana pharmacist or pharmacy license before its expiration date.

The board-issued authorization required for a physical location to operate as a pharmacy, tied to a designated pharmacist-in-charge and compliance with facility standards.

The licensed pharmacist designated on a pharmacy permit who is responsible for the pharmacy's legal compliance, recordkeeping, security, and day-to-day operations.

A community pharmacy permit category allowing dispensing of prescriptions to the general public, with requirements for space, security, references, and pharmacist coverage.

An unlicensed or board-registered support person who assists with dispensing tasks under pharmacist supervision, with limits on clinical judgment and counseling.

The pharmacist's direct discussion with a patient about a new or changed prescription, covering directions, precautions, interactions, and storage, offered in a private area.

The required invitation to discuss a prescription that pharmacy staff must extend to each patient or caregiver, documented when counseling is declined.

Mandatory information on a dispensed container, including pharmacy identity, prescription number, date, patient name, directions, prescriber, drug name and strength, and quantity.

Rules permitting a pharmacist to dispense a therapeutically equivalent generic product unless the prescriber prohibits it, with required patient notification and recordkeeping.

The FDA rating that two drug products are expected to produce the same clinical effect and can generally be interchanged at the same dose.

The FDA publication listing approved drug products with therapeutic equivalence evaluations, used to determine which generics may be substituted for a brand product.

The window during which a prescription may lawfully be filled after it is written, which is shorter for controlled substances and for certain drug classes.

The prescriber's permission, stated on the original prescription, for a pharmacy to dispense additional quantities; limited or prohibited for higher-scheduled drugs.

The federal classification of drugs from Schedule I to V based on abuse potential and accepted medical use, which drives prescribing, refill, and recordkeeping rules.

The federal registration a prescriber or pharmacy must hold to handle controlled substances; it must be renewed periodically and kept at the registered location.

The DEA order form used to transfer Schedule I and II substances between registrants; it must be completed accurately, and copies are retained for a set period.

The DEA's Controlled Substance Ordering System, which lets registrants place Schedule I and II orders electronically using a certificate in place of a paper Form 222.

The prescription monitoring program that collects dispensing data on controlled substances; Louisiana pharmacists must report dispensing and may check the database before dispensing.

The pharmacist's independent duty to judge that a controlled substance prescription was issued for a legitimate medical purpose in the usual course of professional practice.

Warning signs in a controlled substance prescription, such as long distances, cash payment, early refills, or pattern prescribing, that require verification before dispensing.

The documented steps a pharmacist takes to resolve suspicious circumstances, such as contacting the prescriber or checking the monitoring database, before deciding to dispense.

A running record of controlled substances received and dispensed that a pharmacy maintains to reconcile stock and detect losses requiring a DEA report.

The complete count of controlled substances that a registered pharmacy must take every two years, documenting quantities and retaining the record for inspection.

The FDA's ranking of recall severity, from Class I for products likely to cause serious harm to Class III for minor violations, guiding notification and removal steps.

A required pharmacy program that tracks dispensing errors and near misses, analyzes causes, and implements changes to prevent patient harm.

Any preventable event that may cause or lead to inappropriate medication use or patient harm, including prescribing, dispensing, and administration mistakes.

Behavior that violates pharmacy standards or public trust, such as practicing impaired, falsifying records, or dispensing without a valid prescription, and is grounds for discipline.

A licensee whose substance use, mental health condition, or other impairment affects professional performance; boards may require evaluation, treatment, and monitoring.

The legal duty to protect prescription and health information from unauthorized disclosure, permitting release only as authorized by the patient or required by law.

The federal health privacy law whose rules limit how covered pharmacies use and disclose protected health information and require safeguards and patient notices.